Carbamazepine
- Generic Name
- Carbamazepine
- Brand Names
- Carbatrol, Carnexiv, Epitol, Equetro, Tegretol
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12N2O
- CAS Number
- 298-46-4
- Unique Ingredient Identifier
- 33CM23913M
- Background
Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant use...
- Indication
Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia. In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures. Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive e...
- Associated Conditions
- Acute Mania, Alcohol Withdrawal Syndrome, Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Mixed manic depressive episode, Pain, Partial Seizures With Secondary Generalization, Restless Legs Syndrome (RLS)
- Associated Therapies
- -
A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of BI 1810631 in the Blood
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06028464
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06005688
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-10-04
- Target Recruit Count
- 33
- Registration Number
- NCT05994807
- Locations
- 🇺🇸
ICON Phase I Clinic, Salt Lake City, Utah, United States
A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05965219
- Locations
- 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT05932303
- Locations
- 🇨🇦
Local Institution - 0001, Québec, CA, Canada
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT05860933
- Locations
- 🇺🇸
ICON Early Development Services, Salt Lake City, Utah, United States
A Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 144
- Registration Number
- NCT05840952
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT05824143
- Locations
- 🇺🇸
Orlando, Florida, Orlando, Florida, United States
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Dr Cipto Mangunkusumo General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05697614
- Locations
- 🇮🇩
Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia
🇮🇩Harapan Kita Hospital, Jakarta, Indonesia
🇮🇩Fatmawati Hospital, Jakarta, Indonesia
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05594602
- Locations
- 🇺🇸
ICON, plc., Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.